ADC Therapeutics SA 8-K

What Happened
On May 4, 2026, ADC Therapeutics SA announced and filed a press release reporting its financial results for the quarter ended March 31, 2026 (Item 2.02). The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference. The filing is signed by Jose Carmona, Chief Financial Officer of ADC Therapeutics.

Key Details

• Filing date: May 4, 2026 (Current Report on Form 8-K).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Exhibit: Press release dated May 4, 2026 attached as Exhibit 99.1 (contains the detailed financial results).
• Form 8-K signed by Jose Carmona, Chief Financial Officer of ADC Therapeutics.

Why It Matters
Quarterly financial results are the primary source for investors to assess a company's recent revenue, expenses, cash position and operational trends. This 8-K signals ADC’s public update for Q1 2026; investors should read the attached press release (Exhibit 99.1) for the specific earnings, revenue, net income/loss, cash runway and any management commentary that could affect the stock or near-term outlook.